Customize your JAMA Network experience by selecting one or more topics from the list below.
Rosiglitazone is in the thiazolidinedione class of insulin-sensitizing agents used for the treatment of type 2 diabetes mellitus.
Thiazolidinediones have been reported to cause or exacerbate ventricular failure, pulmonary edema, and peripheral edema, especially in patients with left ventricular dysfunction or chronic renal insufficiency.1,2 This case report describes vision loss in a diabetic patient due to rosiglitazone-induced macular edema, which reversed on dosage reduction.
A 55-year-old man noted an insidious decrease in vision in each eye during a 2-week period. He had a history of diabetes mellitus (diagnosed in 1987) complicated by proliferative diabetic retinopathy, neuropathy, and recently discovered nephropathy. Hypertension, hyperlipidemia, and depression were also being treated.
Colucciello M. Vision Loss Due to Macular Edema Induced by Rosiglitazone Treatment of Diabetes Mellitus. Arch Ophthalmol. 2005;123(9):1273–1275. doi:10.1001/archopht.123.9.1273
Create a personal account or sign in to: